Lead sponsor
Octapharma
1 Alzheimer’s disease and related dementias trials led. Source: ClinicalTrials.gov, as of July 21, 2026.
1
Trials led
0
Ongoing
58
Total enrollment
1
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 2
1
Trials by status
Completed
1
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Study of Octagam (Intravenous Immunoglobulin [IVIG]) 10% on the Treatment of Mild to Moderate Alzheimer's DiseaseAlzheimer's diseasePh 2Completed58